Moreover, the HDAC inhibitor SB939 could overcome the deletion of the pro-apoptotic factor BIM (BCL-2 like 11), which is associated with imatinib-resistance (Ng et al., 2012), inducing apoptosis in CML cells harboring a BIM deletion (Rauzan et al., 2017). The gene discussed is HDAC9; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.